tiprankstipranks
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market

Allogene Therapeutics (ALLO) Income Statement

Compare
1,396 Followers

Allogene Therapeutics Income Statement

Last quarter (Q4 2024), Allogene Therapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q4, Allogene Therapeutics's net income was $-59.94M. See Allogene Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 22.00K$ 95.00K$ 243.00K$ 38.49M$ 0.00
Gross Profit
$ 22.00K$ -242.82M$ -16.48M$ 25.42M$ -11.54M
Operating Expenses
$ 273.22M$ 327.83M$ 335.69M$ 294.28M$ 258.24M
Depreciation and Amortization
$ 13.64M$ 14.20M$ 14.29M$ 10.45M$ 11.54M
EBITDA
$ -243.33M$ -300.29M$ -321.24M$ -169.74M$ -250.81M
Operating Income
$ -273.20M$ -327.74M$ -335.45M$ -255.79M$ -258.24M
Other Income/Expenses
$ 16.05M$ 472.00K$ -4.88M$ -1.86M$ 8.02M
Pretax Income
$ -257.15M$ -327.26M$ -332.63M$ -257.00M$ -250.22M
Net Income
$ -257.59M$ -327.26M$ -329.81M$ -244.84M$ -233.47M
Per Share Metrics
Basic EPS
$ -1.32$ -2.09$ -2.30$ -1.80$ -1.94
Diluted EPS
$ -1.32$ -2.09$ -2.30$ -1.80$ -1.94
Weighted Average Shares Outstanding
194.81M 156.93M 143.15M 135.82M 120.37M
Weighted Average Shares Outstanding (Diluted)
194.81M 156.93M 143.15M 135.82M 120.37M
Currency in USD

Allogene Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis